MedTrace Logo

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

NCT01350401 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-01-10

Study results available
· View outcomes & findings →

Summary

The purpose of this early (phase I/II) clinical trial is to assess the effects (both good and bad) of genetically modified T cells after chemotherapy on your cancer and general health.

Conditions

Interventions

GENETIC

Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T

Cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T

Sponsors & Collaborators

  • Adaptimmune

    lead INDUSTRY

Principal Investigators

  • Gerald P Linette, MD, PhD · Washington University School of Medicine

  • Harriet Kluger, MD · Yale New Haven Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-01
Primary Completion
2016-02-17
Completion
2018-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01350401 on ClinicalTrials.gov